Announcement on Changing Signatory Certified Public Accountant
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Announcement on Changing Signatory Certified Public Accountant
Filed with SSE ·
6ix hasn’t read this filing yet.
Earlier from RemeGen
- Earnings Preannouncement for 2025
- Announcement on Vesting Results of Relevant Rights in the Related Vesting Period of the 2022 and 2023 A-share Restricted Stock Incentive Plans and Shares Listing
- Announcement on Completion of Initial Share Repurchase and Implementation of Share Repurchase Plan
- Announcement on Adjusting Upper Limit of Shares Repurchase Price
- Announcement on Signing a Licensing Agreement with AbbVie
Later from RemeGen
- Announcement on Voluntary Disclosure of Approval of Marketing Application for Vedicizumab the Treatment of HER2-Low Expressing Breast Cancer with Liver Metastasis
- 2025 Annual Report
- Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by Dual-antibody ADC Drug RC288 for Injection
- Announcement on Voluntary Disclosure of Approval of Marketing Application for Vedicizumab as the First-line Treatment for HER2-Low Expressing Urothelial Carcinoma
- Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference
Follow RemeGen into a list and get an email when it puts out news.
Follow RemeGen